Dynavax Technologies Corp
(NAS:DVAX)
$
12.955
-0.075 (-0.58%)
Market Cap: 1.71 Bil
Enterprise Value: 1.17 Bil
PE Ratio: 100.23
PB Ratio: 2.51
GF Score: 70/100 Dynavax Technologies Corp at Cowen Healthcare Conference (Virtual) Transcript
Mar 01, 2021 / 08:20PM GMT
Release Date Price:
$8.9
(+1.71%)
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Good afternoon, and welcome once again to Cowen and Company's, hopefully last, Virtual Healthcare Conference. I'm Philip Nadeau, one of Cowen's biotech analysts, and it's my pleasure to moderate a fireside chat with Dynavax Technologies. We have with us Ryan Spencer, CEO; Michael Ostrach, who is in day 1 of his role as CFO emeritus, is also in the background to answer any questions, should they arise. Ryan, thanks for joining us today.
Questions & Answers
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
First, just I wanted to start off with kind of a broad question. Could you give a brief state of the company overview? What are Dynavax's biggest strengths today, its biggest challenges? And what do you think needs to happen to it to continue to create shareholder value?
Ryan Spencer
Dynavax Technologies Corporation - CEO & Director
Well, first, Phil, thanks for
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot